Oral Treatment of Severe Psoriasis With a New Aromatic Retinoid (Ro 10-9359)

The study investigated the oral administration of the aromatic retinoic acid derivative Ro 10-9359 in 25 patients with severe psoriasis, including generalized plaques, erythrodermic, and pustular types. The treatment began with a daily dose of 25 mg/20 kg body weight for 4 weeks, followed by the same dosage every other day for several months, up to 18 months. Excellent results were observed in 16 patients (64%), particularly in those with severe erythrodermic and pustular psoriasis. However, relapses sometimes occurred, necessitating a temporary return to the initial dosage. Notable side effects included cheilitis, palmoplantar scaling, skin thinning, hyperhidrosis, and diffuse hair loss. Some patients also experienced slight increases in transaminases and alkaline phosphatases. Despite these side effects, Ro 10-9359 was considered a very useful new therapy for severe psoriasis.